Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Christopher J Valerio"'
Autor:
Christopher J Valerio, John G Coghlan
Publikováno v:
Vascular Health and Risk Management, Vol 2009, Iss default, Pp 607-619 (2009)
Christopher J Valerio, John G CoghlanDepartment of Cardiology, Royal Free Hospital, London, UKAbstract: Pulmonary arterial hypertension (PAH) is a progressive disease with poor survival outcomes. Bosentan is an oral endothelin-1 receptor antagonist (
Externí odkaz:
https://doaj.org/article/44b0a3ae389a4ab98df5543b13b07d79
To provide an overview of the properties of human serum albumin (HSA), and to review the evidence for the use of human albumin solution (HAS) in critical illness, sepsis and cirrhosis. A MEDLINE search was performed using the terms "human albumin", "
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d9ecd4e40a59a3a128e363a14319a5a
https://europepmc.org/articles/PMC4779163/
https://europepmc.org/articles/PMC4779163/
Autor:
Athol U. Wells, Christopher P. Denton, Benjamin E. Schreiber, Christopher J Valerio, Clive Handler, John G Coghlan, Gregory J. Keir
Publikováno v:
Arthritis & Rheumatism. 63:3531-3539
Objective To construct a readily applicable formula for selecting patients with systemic sclerosis (SSc) for right-sided heart catheterization (RHC) based on the results of their pulmonary function tests (PFTs). Methods The diagnostic value of PFT va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7128701640a8cdac8a0613b3d581bfd
https://doi.org/10.1002/art.30535
https://doi.org/10.1002/art.30535
Autor:
Clive Handler, Christopher P. Denton, Peter Kabunga, Christopher J Valerio, CJ Smith, John G Coghlan
Publikováno v:
Rheumatology. 49:2147-2153
Objectives. To report outcomes in patients with CTD-pulmonary arterial hypertension (CTD-PAH) in an observational cohort treated with bosentan or sitaxentan and determine whether differences would justify a randomized, controlled multicentre study in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdba32d86b7b87fd516db9482e3d985b
https://doi.org/10.1093/rheumatology/keq241
https://doi.org/10.1093/rheumatology/keq241
Autor:
Richard W J Lee, Clive Handler, Helena Edlin, Ian N. Bruce, Christopher P. Denton, Chadi Rakieh, Geoge Kitas, Rhodri Martin, Sheryl Mitchell, Athol U. Wells, Tracey E. Toms, Geraldine Brough, Joanna Shelmerdine, Yasmeen Ahmad, Carol M. Black, Sahena Haque, David D'Cruz, Wan-Fai Ng, Madelynn Chan, Patricia Owen, Mark N. Lazarus, Benjamin E. Schreiber, Tabitha Turner-Stokes, David A. Isenberg, Louise Parker, Christopher J Valerio, Tanaka Ngcozana, J. Dunphy, Gerry Coghlan, Voon H Ong, Neil McHugh, Michael R. Ehrenstein, Maria Juarez, Elizabeth Price, Gregory J. Keir, Simon J. Bowman
Publikováno v:
Rheumatology. 50:iii40-iii42
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcee67218262c1ba360e2836dc5b5abf
https://doi.org/10.1093/rheumatology/ker072
https://doi.org/10.1093/rheumatology/ker072
Autor:
Christopher J, Valerio, Benjamin E, Schreiber, Clive E, Handler, Christopher P, Denton, John G, Coghlan
Publikováno v:
Arthritis and rheumatism. 65(4)
To determine whether patients with systemic sclerosis (SSc) and borderline mean pulmonary artery pressure (PAP) at cardiac catheterization are more likely to develop pulmonary hypertension (PH) than those in whom pulmonary pressure is normal.Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6b8da0cf828819f487b3c8aa9c9f6431
https://pubmed.ncbi.nlm.nih.gov/23280155
https://pubmed.ncbi.nlm.nih.gov/23280155
Publikováno v:
Pulmonary Arterial Hypertension
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7b83a4b691f6db683d3d3870e402f85
https://doi.org/10.1093/med/9780199572632.003.0008
https://doi.org/10.1093/med/9780199572632.003.0008
Publikováno v:
Clinical Medicine Insights: Therapeutics, Vol 1 (2009)
Three different classes of specific therapy exist for pulmonary arterial hypertension. Ambrisentan belongs to the endothelin receptor antagonist (ERA) class of drugs, which inhibit the action of Endothelin-1; a potent vasoconstrictor and mitogen. Unl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7a62cf2180bd9cdae1a1398a24814a3
https://doaj.org/article/d85d33633b8c47bf99ee57e036c551dd
https://doaj.org/article/d85d33633b8c47bf99ee57e036c551dd